Butterfly Network vs Owkin

By valuation, Butterfly Network is the larger company at $1.5B versus $1B — a 1.5x difference. Size can also be measured by team: Butterfly Network employs 500-1000 people while Owkin has 450 employees.

Butterfly Network has raised more in total funding at $700M, compared to Owkin's $334M — a gap of $366M. Combined, the two companies have completed 3 known funding rounds.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Owkin's 69/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 16-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. Owkin was founded by Thomas Clozel in 2016. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems.

Butterfly Network was founded first in 2011, giving it 5 years of additional market experience. Owkin was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while Owkin has approximately 450. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and Owkin are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.